Market capitalization | $287.94m |
Enterprise Value | $205.78m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 10.62 |
P/S ratio (TTM) P/S ratio | 14.87 |
P/B ratio (TTM) P/B ratio | 8.17 |
Revenue growth (TTM) Revenue growth | 346.02% |
Revenue (TTM) Revenue | $19.37m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a ProQR Therapeutics N.V. forecast:
6 Analysts have issued a ProQR Therapeutics N.V. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 19 19 |
346%
346%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -30 -30 |
23%
23%
|
EBIT (Operating Income) EBIT | -33 -33 |
20%
20%
|
Net Profit | -26 -26 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
Head office | Netherlands |
CEO | Daniel Boer |
Employees | 156 |
Founded | 2012 |
Website | www.proqr-tx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.